Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

  • J. Sehouli - (Author)
  • R. Chekerov - (Author)
  • A. Reinthaller - (Author)
  • R. Richter - (Author)
  • A. Gonzalez-Martin - (Author)
  • P. Harter - (Author)
  • H. Woopen - (Author)
  • E. Petru - (Author)
  • L.C. Hanker - (Author)
  • E. Keil - (Author)
  • P. Wimberger - , Department of Gynecology and Obstetrics (Author)
  • P. Klare - (Author)
  • C. Kurzeder - (Author)
  • F. Hilpert - (Author)
  • A.K. Belau - (Author)
  • A. Zeimet - (Author)
  • I. Bover-Barcelo - (Author)
  • U. Canzler - , Department of Gynecology and Obstetrics (Author)
  • S. Mahner - (Author)
  • W. Meier - (Author)

Details

Original languageEnglish
Pages (from-to)2236-2241
Number of pages6
JournalAnnals of Oncology
Publication statusPublished - 2016
Peer-reviewedYes

External IDs

Scopus 85018272687

Keywords